• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

“双打击”细胞遗传学状态可能无法通过基线临床病理特征预测,并且与 B 细胞淋巴瘤患者的总生存高度相关。

'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.

机构信息

Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.

出版信息

Br J Haematol. 2014 Aug;166(3):369-74. doi: 10.1111/bjh.12901. Epub 2014 Apr 25.

DOI:10.1111/bjh.12901
PMID:24761809
Abstract

'Double-Hit' (DH) B cell non-Hodgkin lymphomas are characterized by the presence of a MYC rearrangement and additional rearrangement(s) most commonly involving BCL2 and/or BCL6. Patients with DH lymphomas are unlikely to achieve long-term survival when treated with standard immunochemotherapy alone. DH gene rearrangements can be identified through metaphase karyotyping or more sensitive fluorescence in situ hybridization (FISH), although the latter is not routinely performed. We report 53 cases of B cell lymphoma that underwent diagnostic metaphase karyotying or FISH for MYC rearrangements. DH lymphoma was detected in 17 cases. No baseline factor, including age, serum lactate dehydrogenase, stage, International Prognostic Index or histology predicted for DH status. The median overall survival was significantly shorter for DH compared to non-DH lymphoma patients (8·2 vs. 56·8 months, P < 0·001). DH status retained the most statistically significant association with overall survival on multivariate Cox regression analysis. DH status could not be inferred by baseline disease- or patient-related characteristics and was most predictive of overall survival in this cohort of B cell lymphoma patients. These findings support the practice of routine performance of FISH for DH gene rearrangements on B cell lymphoma specimens in order to effectively identify DH patients who may benefit from risk-adapted therapy.

摘要

“双打击”(DH)B 细胞非霍奇金淋巴瘤的特征是存在 MYC 重排,以及常见的额外重排(s),最常涉及 BCL2 和/或 BCL6。单独采用标准免疫化疗治疗 DH 淋巴瘤患者,长期生存的可能性较低。DH 基因重排可以通过中期核型分析或更敏感的荧光原位杂交(FISH)来识别,尽管后者并非常规进行。我们报告了 53 例接受诊断性中期核型分析或 MYC 重排 FISH 的 B 细胞淋巴瘤病例。在 17 例中检测到 DH 淋巴瘤。没有基线因素,包括年龄、血清乳酸脱氢酶、分期、国际预后指数或组织学,可预测 DH 状态。与非 DH 淋巴瘤患者相比,DH 患者的总生存期明显更短(8.2 与 56.8 个月,P<0.001)。多变量 Cox 回归分析显示,DH 状态与总生存期的相关性最具统计学意义。DH 状态不能通过基线疾病或患者相关特征推断,在该队列的 B 细胞淋巴瘤患者中,它是总生存期的最具预测性因素。这些发现支持在 B 细胞淋巴瘤标本中常规进行 FISH 以检测 DH 基因重排的做法,以便有效识别可能从风险适应治疗中受益的 DH 患者。

相似文献

1
'Double-Hit' cytogenetic status may not be predicted by baseline clinicopathological characteristics and is highly associated with overall survival in B cell lymphoma patients.“双打击”细胞遗传学状态可能无法通过基线临床病理特征预测,并且与 B 细胞淋巴瘤患者的总生存高度相关。
Br J Haematol. 2014 Aug;166(3):369-74. doi: 10.1111/bjh.12901. Epub 2014 Apr 25.
2
Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.具有 BCL6 和 MYC 易位的双打击 B 细胞淋巴瘤是侵袭性的,常为结外淋巴瘤,与 BCL2 双打击 B 细胞淋巴瘤不同。
Am J Surg Pathol. 2013 Mar;37(3):323-32. doi: 10.1097/PAS.0b013e31826cebad.
3
Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements.伴有MYC与BCL2、BCL6或CCND1重排的双打击B细胞淋巴瘤的临床病理特征
Pathol Int. 2015 Oct;65(10):519-27. doi: 10.1111/pin.12335. Epub 2015 Jul 29.
4
Double-hit BCL2/MYC translocations in a consecutive cohort of patients with large B-cell lymphoma - a single centre's experience.双打击 BCL2/MYC 易位在连续队列的弥漫性大 B 细胞淋巴瘤患者中的研究——单中心经验。
Eur J Haematol. 2012 Jul;89(1):63-71. doi: 10.1111/j.1600-0609.2012.01787.x. Epub 2012 Apr 26.
5
MYC rearranged B-cell neoplasms: Impact of genetics on classification.MYC重排的B细胞肿瘤:遗传学对分类的影响。
Cancer Genet. 2016 Oct;209(10):431-439. doi: 10.1016/j.cancergen.2016.08.007. Epub 2016 Sep 14.
6
MYC translocation partner gene determines survival of patients with large B-cell lymphoma with MYC- or double-hit MYC/BCL2 translocations.MYC 易位伙伴基因决定了具有 MYC 或双打击 MYC/BCL2 易位的大 B 细胞淋巴瘤患者的生存。
Eur J Haematol. 2014 Jan;92(1):42-8. doi: 10.1111/ejh.12212. Epub 2013 Nov 11.
7
Cytomorphologic findings of B-cell lymphomas with concurrent IGH/BCL2 and MYC rearrangements (dual-translocation lymphomas).IGH/BCL2 和 MYC 重排(双转录淋巴瘤)的 B 细胞淋巴瘤的细胞形态学发现。
Cancer Cytopathol. 2011 Aug 25;119(4):254-62. doi: 10.1002/cncy.20156. Epub 2011 May 10.
8
MYC/BCL2 double-hit high-grade B-cell lymphoma.MYC/BCL2 双打击高级别 B 细胞淋巴瘤。
Adv Anat Pathol. 2013 Sep;20(5):315-26. doi: 10.1097/PAP.0b013e3182a289f2.
9
Frequent aberrations of chromosome 8 in aggressive B-cell non-Hodgkin lymphoma.侵袭性B细胞非霍奇金淋巴瘤中8号染色体频繁畸变。
Cancer Genet Cytogenet. 2005 Jan 15;156(2):114-21. doi: 10.1016/j.cancergencyto.2004.04.009.
10
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.B 细胞淋巴瘤,分类不明,弥漫性大 B 细胞淋巴瘤和伯基特淋巴瘤之间的特征:39 例研究。
Br J Haematol. 2013 Jul;162(1):40-9. doi: 10.1111/bjh.12343. Epub 2013 Apr 18.

引用本文的文献

1
MYC rearrangements in HIV-associated large B-cell lymphomas: EUROMYC, a European retrospective study.HIV 相关弥漫性大 B 细胞淋巴瘤中的 MYC 重排:EUROMYC,一项欧洲回顾性研究。
Blood Adv. 2024 Feb 27;8(4):968-977. doi: 10.1182/bloodadvances.2023010704.
2
Induction treatment in high-grade B-cell lymphoma with a concurrent and and/or rearrangement: a systematic review and meta-analysis.伴有同时发生的 及 和/或 重排的高级别B细胞淋巴瘤的诱导治疗:一项系统评价和荟萃分析
Front Oncol. 2023 Jul 20;13:1188478. doi: 10.3389/fonc.2023.1188478. eCollection 2023.
3
Rituximab-Based Therapy in Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients: Individualized Risk-Adapted Therapy Approach Using Molecular Subtypes.
基于利妥昔单抗的疗法用于新诊断的弥漫性大B细胞淋巴瘤患者:采用分子亚型的个体化风险适应性治疗方法
J Hematol. 2017 Sep;6(2-3):33-43. doi: 10.14740/jh320w. Epub 2017 Jul 20.
4
Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas.LMO2检测对侵袭性大B细胞淋巴瘤诊断的临床意义
Cancers (Basel). 2020 Apr 5;12(4):884. doi: 10.3390/cancers12040884.
5
Molecular Risk Stratification in Aggressive B-Cell Lymphomas.侵袭性B细胞淋巴瘤的分子风险分层
J Clin Oncol. 2020 Jun 20;38(18):2014-2017. doi: 10.1200/JCO.19.03069. Epub 2020 Apr 2.
6
An increase in copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens.拷贝数增加对弥漫性大 B 细胞淋巴瘤和高级别淋巴瘤患者具有进行性的负预后影响,这些患者可能从强化治疗方案中获益。
Haematologica. 2020 May;105(5):1369-1378. doi: 10.3324/haematol.2019.223891. Epub 2019 Aug 8.
7
C-MYC and BCL2: Correlation between Protein Over-Expression and Gene Translocation and Impact on Outcome in Diffuse Large B Cell Lymphoma.C-MYC与BCL2:弥漫性大B细胞淋巴瘤中蛋白过表达与基因易位的相关性及其对预后的影响
Asian Pac J Cancer Prev. 2019 May 25;20(5):1463-1470. doi: 10.31557/APJCP.2019.20.5.1463.
8
Correlation Between C-MYC, BCL-2, and BCL-6 Protein Expression and Gene Translocation as Biomarkers in Diagnosis and Prognosis of Diffuse Large B-cell Lymphoma.C-MYC、BCL-2和BCL-6蛋白表达及基因易位作为弥漫性大B细胞淋巴瘤诊断和预后生物标志物的相关性
Front Pharmacol. 2019 Jan 7;9:1497. doi: 10.3389/fphar.2018.01497. eCollection 2018.
9
Inferior survival in high-grade B-cell lymphoma with and and/or rearrangements is not associated with gene rearrangements.伴有 和/或 重排的高级别 B 细胞淋巴瘤患者的生存情况较差,但与 基因重排无关。
Haematologica. 2018 Nov;103(11):1899-1907. doi: 10.3324/haematol.2018.190157. Epub 2018 Jun 14.
10
Advancing the management of double hit lymphoma.推进双打击淋巴瘤的管理。
Oncotarget. 2017 Sep 9;8(45):78245-78246. doi: 10.18632/oncotarget.20794. eCollection 2017 Oct 3.